Comparative Performance of LFA-REAL, SLEDAI, and BILAG for Detecting Clinically Meaningful Changes in Lupus Activity

Area of Science:

• Rheumatology
• Clinical Immunology
• Systemic Lupus Erythematosus (SLE)

Background:

• Accurate assessment of Systemic Lupus Erythematosus (SLE) disease activity is crucial for guiding treatment decisions.
• Existing indices like BILAG and SLEDAI have limitations in capturing clinician-perceived changes.
• The LFA-REAL index is a newer tool for evaluating SLE disease activity.

Purpose of the Study:

• To compare the performance of LFA-REAL, BILAG, and SLEDAI in detecting clinician-rated improvement and worsening of SLE.
• To evaluate the ability of these indices to identify patients needing treatment escalation.
• To assess the utility of LFA-REAL in clinical practice and research.

Main Methods:

• Prospective, observational study at four centers involving adult SLE patients.
• Disease activity assessed using SLEDAI, BILAG, and LFA-REAL by the same physician at baseline and follow-up.
• Clinician's Global Impression of Change (CGIC) used to categorize patient status; ROC analysis with Youden-Index for optimal cut-offs.

Main Results:

• LFA-REAL showed superior performance in detecting improvement (AUC 0.85) and worsening (AUC 0.86) compared to BILAG and SLEDAI.
• LFA-REAL identified all patients (100%) requiring treatment escalation, significantly outperforming BILAG (50%) and SLEDAI (25%).
• A statistically significant advantage of LFA-REAL over SLEDAI was observed for detecting improvement.

Conclusions:

• LFA-REAL demonstrates comparable and in some aspects superior performance to BILAG and SLEDAI for assessing SLE disease activity.
• Its ability to detect clinician-rated changes and identify patients needing treatment escalation supports its use.
• LFA-REAL is a valuable metric for SLE disease activity in clinical practice and research.